We have four programs: One of these programs is at the pre-NDA filing stage, two are in clinical development, and one is at an early stage of development. Each is intended to treat gout or rare and progressive kidney diseases, all of which are modulated by aberrant purine and uric acid metabolism.
We are currently developing XRx-026 for the treatment of allopurinol intolerant gout patients. Allopurinol intolerance occurs in 3-5% of gout patients receiving allopurinol treatment, the current standard of care for gout. The medication previously used by allopurinol intolerant gout patients, febuxostat, now carries a severe Black Box warning resulting in an exciting opportunity for our gout program which is approaching an NDA filing.
Learn More
We are developing XRx-008 for the treatment of progressive autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder that’s known to cause declining kidney function leading to end-stage kidney disease and cardiovascular disease.
Learn More
XRx-101 is a novel proprietary formulation of oxypurinol that has the potential to treat acute kidney disease and other health consequences that are associated with serious viral infections.
Learn More
XORTX is co-developing XRx-225 for the treatment of Type 2 Diabetic Nephropathy (T2DN), one of the most common causes of chronic kidney failure and end-stage kidney disease.
Learn More
We believe there is a substantial benefit in collaborating with partners. We are always on the lookout for opportunities to develop and commercialize products that will help redefine the future of treatment options for patients with gout and progressive kidney diseases.
Receive updates straight into your inbox